nach oben

Virchows Archiv

Erschienen in:

01.06.2014 | Original Article

HNF4A immunohistochemistry facilitates distinction between primary and metastatic breast and gastric carcinoma

verfasst von: R. S. van der Post, P. Bult, I. P. Vogelaar, M. J. L. Ligtenberg, N. Hoogerbrugge, J. H. van Krieken

Erschienen in: Virchows Archiv | Ausgabe 6/2014

Einloggen, um Zugang zu erhalten

Abstract

The distinction between primary gastric adenocarcinoma and gastric metastatic breast carcinoma can be difficult. Expression of hepatocyte nuclear factor 4A (HNF4A) has been described as being specific to distinguish between neoplastic gastric and breast epithelial cells. The aim of this study was to validate the use of HNF4A with immunohistochemistry in discriminating gastric from breast carcinomas. Immunohistochemical expressions of HNF4A, estrogen receptor (ER), progesterone receptor (PR), and BRST-2 were determined in primary sporadic gastric adenocarcinomas (n = 107) and breast carcinomas (n = 105). The same markers and clinicopathological features were studied in 1 patient with breast metastasis of gastric cancer, 6 patients with gastric metastases of breast cancer, and 13 patients with both primary gastric and breast carcinomas. HNF4A expression was seen in 106 of 107 primary gastric adenocarcinomas and was absent in all 105 primary breast carcinomas (sensitivity 99 %, specificity 100 %). ER, PR, and BRST-2 were 100 % specific for breast carcinomas with sensitivities of 77, 58, and 38 %, respectively. The metastasis of gastric carcinoma to the breast showed strong expression of HNF4A. None of the metastases of breast carcinomas to the stomach showed expression of HNF4A. Tissues of patients with two primary carcinomas showed strong expression of HNF4A in all gastric carcinomas and no expression in breast carcinomas. Our results indicate that HNF4A is a very good marker to discriminate between primary and metastatic gastric and breast carcinomas.

Fitzgerald RC, Hardwick R, Huntsman D, Carneiro F, Guilford P, Blair V, Chung DC, Norton J, Ragunath K, Van Krieken JH, Dwerryhouse S, Caldas C (2010) Hereditary diffuse gastric cancer: updated consensus guidelines for clinical management and directions for future research. J Med Genet 47:436–444, 2010/07/02 edn. doi:10.1136/jmg.2009.074237 PubMedCentralPubMedCrossRef

Pharoah PD, Guilford P, Caldas C (2001) Incidence of gastric cancer and breast cancer in CDH1 (E-cadherin) mutation carriers from hereditary diffuse gastric cancer families. Gastroenterology 121:1348–1353, 2001/12/01 ednPubMedCrossRef

Benusiglio PR, Malka D, Rouleau E, De Pauw A, Buecher B, Nogues C, Fourme E, Colas C, Coulet F, Warcoin M, Grandjouan S, Sezeur A, Laurent-Puig P, Moliere D, Tlemsani C, Di Maria M, Byrde V, Delaloge S, Blayau M, Caron O (2013) CDH1 germline mutations and the hereditary diffuse gastric and lobular breast cancer syndrome: a multicentre study. J Med Genet 50:486–489, 2013/05/28 edn. doi:10.1136/jmedgenet-2012-101472 PubMedCrossRef

Jakubowska A, Scott R, Menkiszak J, Gronwald J, Byrski T, Huzarski T, Gorski B, Cybulski C, Debniak T, Kowalska E, Starzynska T, Lawniczak M, Narod S, Lubinski J (2003) A high frequency of BRCA2 gene mutations in Polish families with ovarian and stomach cancer. Eur J Hum Genet 11:955–958, 2003/12/03 edn. doi:10.1038/sj.ejhg.5201064 PubMedCrossRef

Friedenson B (2005) BRCA1 and BRCA2 pathways and the risk of cancers other than breast or ovarian. MedGenMed 7:60, 2005/12/22 ednPubMedCentralPubMed

Moran A, O’Hara C, Khan S, Shack L, Woodward E, Maher ER, Lalloo F, Evans DG (2012) Risk of cancer other than breast or ovarian in individuals with BRCA1 and BRCA2 mutations. Fam Cancer 11:235–242, 2011/12/22 edn. doi:10.1007/s10689-011-9506-2 PubMedCrossRef

Graham WP 3rd (1964) Gastro-intestinal metastases from carcinoma of the breast. Ann Surg 159:477–480, 1964/03/01 ednPubMedCentralPubMedCrossRef

Choi SH, Sheehan FR, Pickren JW (1964) Metastatic involvement of the stomach by breast cancer. Cancer 17:791–797, 1964/06/01 ednPubMedCrossRef

Cifuentes N, Pickren JW (1979) Metastases from carcinoma of mammary gland: an autopsy study. J Surg Oncol 11:193–205, 1979/01/01 ednPubMedCrossRef

10.

Reiman T, Butts CA (2001) Upper gastrointestinal bleeding as a metastatic manifestation of breast cancer: a case report and review of the literature. Can J Gastroenterol 15:67–71, 2001/03/16 ednPubMed

11.

Almubarak MM, Lae M, Cacheux W, de Cremoux P, Pierga JY, Reyal F, Bennett SP, Falcou MC, Salmon RJ, Baranger B, Mariani P (2011) Gastric metastasis of breast cancer: a single centre retrospective study. Dig Liver Dis 43:823–827, 2011/05/28 edn. doi:10.1016/j.dld.2011.04.009 PubMedCrossRef

12.

BG Taal, FC den Hartog Jager, R Steinmetz and H Peterse (1992) The spectrum of gastrointestinal metastases of breast carcinoma: I. Stomach. Gastrointest Endosc, vol 38, 1992/03/01 edn.,

13.

Sato T, Muto I, Fushiki M, Hasegawa M, Hasegawa M, Sakai T, Sekiya M (2008) Metastatic breast cancer from gastric and ovarian cancer, mimicking inflammatory breast cancer: report of two cases. Breast Cancer 15:315–320, 2008/03/04 edn. doi:10.1007/s12282-008-0040-5 PubMedCrossRef

14.

Hamby LS, McGrath PC, Cibull ML, Schwartz RW (1991) Gastric carcinoma metastatic to the breast. J Surg Oncol 48:117–121, 1991/10/01 ednPubMedCrossRef

15.

Boutis AL, Andreadis C, Patakiouta F, Mouratidou D (2006) Gastric signet-ring adenocarcinoma presenting with breast metastasis. World J Gastroenterol 12:2958–2961, 2006/05/24 ednPubMed

16.

Koyama T, Sekine S, Taniguchi H, Tsuda H, Ikegami M, Hano H, Kushima R (2011) Hepatocyte nuclear factor 4A expression discriminates gastric involvement by metastatic breast carcinomas from primary gastric adenocarcinomas. Hum Pathol 42:1777–1784, 2011/07/08 edn. doi:10.1016/j.humpath.2011.04.002 PubMedCrossRef

17.

Kojima K, Kishimoto T, Nagai Y, Tanizawa T, Nakatani Y, Miyazaki M, Ishikura H (2006) The expression of hepatocyte nuclear factor-4alpha, a developmental regulator of visceral endoderm, correlates with the intestinal phenotype of gastric adenocarcinomas. Pathology 38:548–554, 2007/03/31 ednPubMedCrossRef

18.

Tanaka T, Jiang S, Hotta H, Takano K, Iwanari H, Sumi K, Daigo K, Ohashi R, Sugai M, Ikegame C, Umezu H, Hirayama Y, Midorikawa Y, Hippo Y, Watanabe A, Uchiyama Y, Hasegawa G, Reid P, Aburatani H, Hamakubo T, Sakai J, Naito M, Kodama T (2006) Dysregulated expression of P1 and P2 promoter-driven hepatocyte nuclear factor-4alpha in the pathogenesis of human cancer. J Pathol 208:662–672, 2006/01/10 edn. doi:10.1002/path.1928 PubMedCrossRef

19.

Sladek FM, Zhong WM, Lai E, Darnell JE Jr (1990) Liver-enriched transcription factor HNF-4 is a novel member of the steroid hormone receptor superfamily. Genes Dev 4:2353–2365, 1990/12/01 ednPubMedCrossRef

20.

Takano K, Hasegawa G, Jiang S, Kurosaki I, Hatakeyama K, Iwanari H, Tanaka T, Hamakubo T, Kodama T, Naito M (2009) Immunohistochemical staining for P1 and P2 promoter-driven hepatocyte nuclear factor-4alpha may complement mucin phenotype of differentiated-type early gastric carcinoma. Pathol Int 59:462–470, 2009/07/01 edn. doi:10.1111/j.1440-1827.2009.02394.x PubMedCrossRef

21.

Sugai M, Umezu H, Yamamoto T, Jiang S, Iwanari H, Tanaka T, Hamakubo T, Kodama T, Naito M (2008) Expression of hepatocyte nuclear factor 4 alpha in primary ovarian mucinous tumors. Pathol Int 58:681–686, 2008/10/11 edn. doi:10.1111/j.1440-1827.2008.02293.x PubMedCrossRef

22.

Chu PG, Weiss LM (2004) Immunohistochemical characterization of signet-ring cell carcinomas of the stomach, breast, and colon. Am J Clin Pathol 121:884–892, 2004/06/17 edn. doi:10.1309/a09e-rymf-r64n-erdw PubMedCrossRef

23.

O’Connell FP, Wang HH, Odze RD (2005) Utility of immunohistochemistry in distinguishing primary adenocarcinomas from metastatic breast carcinomas in the gastrointestinal tract. Arch Pathol Lab Med 129:338–347, 2005/03/02 edn. doi:10.1043/1543-2165(2005)129<338:uoiidp>2.0.co;2 PubMed

24.

Tot T (2000) The role of cytokeratins 20 and 7 and estrogen receptor analysis in separation of metastatic lobular carcinoma of the breast and metastatic signet ring cell carcinoma of the gastrointestinal tract. APMIS 108:467–472, 2000/10/12 ednPubMedCrossRef

25.

Chu PG, Chung L, Weiss LM, Lau SK (2011) Determining the site of origin of mucinous adenocarcinoma: an immunohistochemical study of 175 cases. Am J Surg Pathol 35:1830–1836, 2011/09/02 edn. doi:10.1097/PAS.0b013e3182299c25 PubMedCrossRef

26.

Werling RW, Yaziji H, Bacchi CE, Gown AM (2003) CDX2, a highly sensitive and specific marker of adenocarcinomas of intestinal origin: an immunohistochemical survey of 476 primary and metastatic carcinomas. Am J Surg Pathol 27:303–310, 2003/02/27 ednPubMedCrossRef

27.

Dennis JL, Hvidsten TR, Wit EC, Komorowski J, Bell AK, Downie I, Mooney J, Verbeke C, Bellamy C, Keith WN, Oien KA (2005) Markers of adenocarcinoma characteristic of the site of origin: development of a diagnostic algorithm. Clin Cancer Res 11:3766–3772, 2005/05/18 edn. doi:10.1158/1078-0432.ccr-04-2236 PubMedCrossRef

28.

Moll R, Lowe A, Laufer J, Franke WW (1992) Cytokeratin 20 in human carcinomas. A new histodiagnostic marker detected by monoclonal antibodies. Am J Pathol 140:427–447, 1992/02/01 ednPubMedCentralPubMed

29.

Nguyen MD, Plasil B, Wen P, Frankel WL (2006) Mucin profiles in signet-ring cell carcinoma. Arch Pathol Lab Med 130:799–804PubMed

30.

Lau SK, Weiss LM, Chu PG (2004) Differential expression of MUC1, MUC2, and MUC5AC in carcinomas of various sites: an immunohistochemical study. Am J Clin Pathol 122:61–69PubMedCrossRef

Titel: HNF4A immunohistochemistry facilitates distinction between primary and metastatic breast and gastric carcinoma
verfasst von: R. S. van der Post
P. Bult
I. P. Vogelaar
M. J. L. Ligtenberg
N. Hoogerbrugge
J. H. van Krieken
Publikationsdatum: 01.06.2014
Verlag: Springer Berlin Heidelberg
Erschienen in: Virchows Archiv / Ausgabe 6/2014
Print ISSN: 0945-6317
Elektronische ISSN: 1432-2307
DOI: https://doi.org/10.1007/s00428-014-1574-x

Springer Medizin

HNF4A immunohistochemistry facilitates distinction between primary and metastatic breast and gastric carcinoma

Abstract

Neu im Fachgebiet Pathologie

Molekularpathologische Untersuchungen im Wandel der Zeit

Vergleichende Pathologie in der onkologischen Forschung

Gastrointestinale Stromatumoren

Personalisierte Medizin in der Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2014

BUB1 mRNA is significantly co-expressed with AURKA and AURKB mRNA in advanced-stage ovarian serous carcinoma

Loss of nuclear prothymosin-α expression is associated with disease progression in human superficial bladder cancer

Coronary cardiac allograft vasculopathy versus native atherosclerosis: difficulties in classification

VE1 immunohistochemistry accurately detects BRAF V600E mutations in colorectal carcinoma and can be utilized in the detection of poorly differentiated colorectal serrated adenocarcinoma

Type AB thymoma is not a mixed tumor of type A and type B thymomas, but a distinct type of thymoma

Defined morphological criteria allow reliable diagnosis of colorectal serrated polyps and predict polyp genetics

Neu im Fachgebiet Pathologie

Molekularpathologische Untersuchungen im Wandel der Zeit

Vergleichende Pathologie in der onkologischen Forschung

Gastrointestinale Stromatumoren

Personalisierte Medizin in der Onkologie